SCHEMBL22220046

SCHEMBL22220046

COC(=O)C1(C(=O)NCCCCCN2C(=O)C=CC2=O)CCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 5/20 0.41
▸ FAAH O00519 3/20 0.41
▸ HPGD P15428 2/20 0.41
▸ HTT P42858 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ HSP90AA1 P07900 1/20 0.41
▸ TLR9 Q9NR96 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ XBP1 P17861 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ GPR35 Q9HC97 1/20 0.41
▸ GPR55 Q9Y2T6 1/20 0.41
▸ PTGS1 P23219 7/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16834912 0.89 DRD2 (0.39) MGLLFAAHHPGDHTTSMN1; SMN2
SCHEMBL18100026 0.88 MGLL (0.44) MGLLFAAHHPGDHTTSMN1; SMN2
SCHEMBL17813682 0.87 MGLL (0.36) MGLLFAAHHPGDHTTSMN1; SMN2
SCHEMBL16847675 0.87 PTGS1 (0.44) MGLLFAAHHPGDHTTSMN1; SMN2
SCHEMBL16834889 0.86 PTGS1 (0.47) MGLLFAAHHPGDHTTSMN1; SMN2
SCHEMBL19666091 0.85 MGLL (0.37) MGLLFAAHHPGDHTTSMN1; SMN2
SCHEMBL17813686 0.82 OPRM1 (0.34) MGLLFAAHHPGDHTTSMN1; SMN2
SCHEMBL23889659 0.82 DRD2 (0.49) MGLLFAAHHPGDHTTSMN1; SMN2
SCHEMBL22698762 0.82 MGLL (0.41) MGLLFAAHHPGDHTTSMN1; SMN2
SCHEMBL19061723 0.78 MGLL (0.44) MGLLFAAHHPGDHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648315-B2 Silvestrol antibody-drug conjugates and methods of use GENENTECH, INC. (US) 2023-05-16 — — US disclosed
US-20200222545-A1 SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE GENENTECH, INC. (US) 2020-07-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200222545-A1 SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE SHBG, EPCAM, ITGAV MGLL 2142/4885FAAH 1636/4885HPGD 1968/4885
US-11648315-B2 Silvestrol antibody-drug conjugates and methods of use SHBG, EPCAM, ITGAV MGLL 2142/4885FAAH 1636/4885HPGD 1968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback